Leonhardt's Launchpads To Unveil Valvublator II Simplified Catheter Based System for Regenerating Heart Valves

  Back to News

  United States, California, Los Angeles - 09/26/2019 (PRDistribution.com)


Valuvublator, a development stage medical device company with a patented pending heart valve decalcification and regeneration platform de

signed with intent to help people keep their own heart valves instead of getting a cow, pig, steel or plastic artificial implant, is showcasing its innovative platform at an Innovation Showcase and DEMO DAY to be held Friday, September 27th in Palo Alto. The platform features the only system known to not only decalcify diseased heart valves but also to regenerate them and prevent them from re-calcifying over the long term.  

Animation Video Link to the Valvublator II design  https://vimeo.com/361935548/5ba8932782

 

The Valvublator II design is a unique system platform addressing heart valve decalcification, regeneration and prevention of re-calcifiation:

end of a percutaneous catheter.  Easy to place in position. 

Step 1 = ultrasonic energy to break up calcification. 

Step 2 = delivery of precise bioelectric signaling sequences to release stem cell homing proteins and other regeneration promoting factors.

Step 3 = at home application of simple electrodes on thigh muscle 1X a month for 15 minutes to release circulating Klotho to prevent re-calcificaiton. 

Step 4 =   


"Natural heart valves undeniably out perform any tissue or mechanical artificial heart valve.  Both open chest and percutaneous heart valve replacements have associated risks" said Mark Cunningham, MD, a cardiac surgeon at USC Keck Medical Center and Chief Scientific Advisor to Valvublator.  


"Natural heart valves undeniably out perform any tissue or mechanical artificial heart valve.  Both open chest and percutaneous heart valve replacements have associated risks" said Mark Cunningham, MD, a cardiac surgeon at USC Keck Medical Center and Chief Scientific Advisor to Valvublator.  

"Natural heart valves undeniably out perform any tissue or mechanical artificial heart valve.  Both open chest and percutaneous heart valve replacements have associated risks" said Mark Cunningham, MD, a cardiac surgeon at USC Keck Medical Center and Chief Scientific Advisor to Valvublator. 

  


"Natural heart valves undeniably out perform any tissue or mechanical artificial heart valve.  Both open chest and percutaneous heart valve replacements have associated risks" said Mark Cunningham, MD, a cardiac surgeon at USC Keck Medical Center and Chief Scientific Advisor to Valvublator.  

In the United States, surgeons perform over 110,000 heart valve operations each year. Nearly all of these operations are done to repair or replace the mitral or aortic valves. These valves are on the left side of the heart, which works harder than the right. They control the flow of oxygen-rich blood from the lungs to the rest of the body. If valve damage is mild, doctors may be able to treat it with medicines. If damage to the valve is severe, surgery to repair or replace the valve may be needed.

“This simple to use system may be another choice for patients suffering of heart valve disease. In the future we hope this product may be used to clean up and regenerate heart valves BEFORE they are so advanced in disease that a replacement is deemed necessary."  stated Dr. Brett Burton Vice President of R&D at Valvublator lead engineer working on the project.  “This simple procedure could address a significant portion of patients who otherwise would be referred to open-heart or transcatheter based heart valve replacement, allowing them to keep their own heart valve instead." 

Valvublator is in the early stages of gathering pre-clinical data with intent to soon file a pre-submission with the FDA to define its clinical pathway leading to a PMA. The company also is defining its regulatory and clinical strategy for OUS clinical studies. The Valvublator device will always be used with commercially available FDA or CE Mark cleared cerebral/emboli protection devices to capture or deflect any stray fragments. 

About Valvublator:  

Valvublator, www.valvublator.com, is a development-stage medical device company developing an innovative platform for simple treatment to permit patients to keep their own heart valves decalcified and regenerated instead of getting cow, pig, plastic or steel artificial implants.  Valvublator is incubating within the Leonhardt's Lauchpads accelerator labs in Los Angeles, Utah, Pittsburgh and Brazil.  The Valvublator II design was developed in collaboration with REV1 Engineering of California - https://rev1engineering.com


 

About Leonhardt's Launchpads Innovation Showcases and DEMO DAYS Organ Regeneration 2019:  

Leonhardt's Launchpads will showcase 30 startups from its 2019 portfolio class all focused on organ regeneration and recovery including Valvublator:

Contacts:

For Valvublator:

Dr. Brett Burton, VP of R&D, [email protected]

Brian Hardy, Director of Marketing, brian[email protected]

Phone: (424) 291-2133
 

web sites:  www.valvublator.com
 

Leonhardt's Launchpads by Cal-X Stars, 12655 W Jefferson Blvd, Los Angeles, CA 90066
 


Leonhardt's Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115

Media Contacts:

person_outline  Full Name:Howard J. Leonhardt
phone  Phone Number: (424) 291-2133
business_center  Company:Leonhardt' Launchapds - Valublator
language  Website:valvublator.com
mail_outline  
View Results in Google
Promote Your Business keyboard_arrow_right

Join The Community

Whitepaper

10 Simple Things To Boost Your PR in 2019

  1. Use Video for B2B
  2. Research the Language of Your Customers
  3. Leverage Imagery for Virality
  4. Prioritize SEO to Improve Conversions
  5. Know Journalists' Needs
  6. Strategize for Earned Media
  7. Keep Blogging
  8. Expand Your Research
  9. Stick to Facts: Counter Fake News
  10. Position Content for Outreach
    100% spam free. We promise to keep your email safe.